SS
IOBT

SBI Securities’s IO Biotech IOBT Stock Holding History

SBI Securities’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-122
Closed -$74 – 4092
2025
Q4 		$74 Hold
122
– – ﹤0.01% 3503
2025
Q3 		$44 Sell
122
-10
-8% -$17 ﹤0.01% 3751
2025
Q2 		$183 Buy
132
+2
+2% +$2 ﹤0.01% 3345
2025
Q1 		$142 Hold
130
– – ﹤0.01% 3326
2024
Q4 		$120 Buy
+130
New +$129 ﹤0.01% 3405

Other funds holding IOBT

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

SBI Securities's IOBT Position: Q1 2026 in Review

SBI Securities sold out of IO Biotech (IOBT) in Q1 2026, closing a stake of 122 shares — an estimated $74 sold.

SBI Securities first reported a position in IOBT in Q4 2024 and held it in 5 quarters. The position peaked at $183 in Q2 2025. 12 funds tracked by Wall St. Rank hold IOBT as of Q1 2026.

  • SBI Securities reported no remaining IO Biotech position as of Q1 2026 after selling out during the quarter.
  • SBI Securities sold 122 IO Biotech shares in Q1 2026, an estimated $74.
  • SBI Securities first reported a position in IO Biotech in Q4 2024 and held it in 5 quarters.
  • SBI Securities's IO Biotech position peaked at $183 in Q2 2025.
  • 12 funds tracked by Wall St. Rank held IO Biotech as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.